During the last session, Akebia Therapeutics Inc. (NASDAQ:AKBA)’s traded shares were 1.87 million, with the beta value of the company hitting 0.77. At the end of the trading day, the stock’s price was $1.35, reflecting an intraday loss of -0.74% or -$0.01. The 52-week high for the AKBA share is $2.48, that puts it down -83.7 from that peak though still a striking 42.22% gain since the share price plummeted to a 52-week low of $0.78. The company’s market capitalization is $282.96M, and the average intraday trading volume over the past 10 days was 3.04 million shares, and the average trade volume was 3.26 million shares over the past three months.
Akebia Therapeutics Inc. (AKBA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AKBA has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Akebia Therapeutics Inc. (NASDAQ:AKBA) trade information
Akebia Therapeutics Inc. (AKBA) registered a -0.74% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.74% in intraday trading to $1.35, hitting a weekly high. The stock’s 5-day price performance is 7.14%, and it has moved by 33.66% in 30 days. Based on these gigs, the overall price performance for the year is 8.87%. The short interest in Akebia Therapeutics Inc. (NASDAQ:AKBA) is 13.11 million shares and it means that shorts have 3.4 day(s) to cover.
The extremes of the forecast give a target low and a target high price of $6 and $7 respectively. As a result, AKBA is trading at a discount of -418.52% off the target high and -344.44% off the low.
Akebia Therapeutics Inc. (AKBA) estimates and forecasts
Statistics show that Akebia Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Akebia Therapeutics Inc. (AKBA) shares have gone down -3.57% during the last six months, with a year-to-date growth rate less than the industry average at 0.00% against 13.00.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 35.46%. While earnings are projected to return 7.02% in 2024.
AKBA Dividends
Akebia Therapeutics Inc. is due to release its next quarterly earnings in August. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Akebia Therapeutics Inc. (NASDAQ:AKBA)’s Major holders
The next largest institutional holding, with 8.23 million shares, is of VANGUARD GROUP INC’s that is approximately 4.3317% of outstanding shares. At the market price on 2024-03-31, these shares were valued at $15.05 million.
